Immunizations could be administered within minutes where and when a disease is breaking out.
Vaccines combat diseases and protect populations from outbreaks, but the life-saving technology leaves room for improvement. Vaccines usually are made en masse in centralized locations far removed from where they will be used. They are expensive to ship and keep refrigerated and they tend to have short shelf lives.
University of Washington engineers hope a new type of vaccine they have shown to work in mice will one day make it cheaper and easy to manufacture on-demand vaccines for humans. Immunizations could be administered within minutes where and when a disease is breaking out.
“We’re really excited about this technology because it makes it possible to produce a vaccine on the spot. For instance, a field doctor could see the beginnings of an epidemic, make vaccine doses right away, and blanket vaccinate the entire population in the affected area to prevent the spread of an epidemic,” said François Baneyx, a UW professor of chemical engineering and lead author of a recent paper published online in the journal Nanomedicine.
The research was funded by a Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation and the National Institutes of Health.
In typical vaccines, weakened pathogens or proteins found on the surface of microbes and viruses are injected into the body along with compounds called adjuvants to prepare a person’s immune system to fight a particular disease. But standard formulations don’t always work, and the field is seeking ways to manufacture vaccines quicker, cheaper and tailored to specific infectious agents, Baneyx said.
The UW team injected mice with nanoparticles synthesized using an engineered protein that both mimics the effect of an infection and binds to calcium phosphate, the inorganic compound found in teeth and bones. After eight months, mice that contracted the disease made threefold the number of protective “killer” T-cells – a sign of a long-lasting immune response – compared with mice that had received the protein but no calcium phosphate nanoparticles.
The nanoparticles appear to work by ferrying the protein to the lymph nodes where they have a higher chance of meeting dendritic cells, a type of immune cell that is scarce in the skin and muscles, but plays a key role in activating strong immune responses.
In a real-life scenario, genetically engineered proteins based on those displayed at the surface of pathogens would be freeze-dried or dehydrated and mixed with water, calcium and phosphate to make the nanoparticles. This should work with many different diseases and be especially useful for viral infections that are hard to vaccinate against, Baneyx said.
He cautioned, however, that it has only been proven in mice, and the development of vaccines using this method hasn’t begun for humans.
The Latest on: On-demand vaccines
[google_news title=”” keyword=”On-demand vaccines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: On-demand vaccines
- AstraZeneca Pulls Covid Shot due to Low Demandon May 13, 2024 at 5:31 am
UK based drug-maker, AstraZeneca, is pulling its covid-19 vaccine from global markets due to low demand. They have been one of the main covid-19 vaccines worldwide, producing more than three billion ...
- Novavax Stock Doubles on $1.2B Sanofi Deal for COVID-19, Flu Vaccineson May 10, 2024 at 7:36 am
Novavax shares more than doubled in intraday trading Friday as it announced a $1.2 billion deal to license its vaccine technology to Sanofi. Novavax will co-commercialize its COVID-19 vaccine with the ...
- A new cholera vaccine will increase supply, but will it be enough to manage global outbreaks?on May 9, 2024 at 1:31 am
Along with a new manufacturing plant that will be at full capacity next year, EuBiologics will be able to produce 50 million cholera vaccine doses in 2024, and 80 million in 2025, said Lynch — most of ...
- AstraZeneca Is Withdrawing Its Covid Vaccine Worldwide, Citing Low Demandon May 8, 2024 at 10:58 am
AstraZeneca has started to pull its Covid-19 vaccine from global markets because of low demand, the pharmaceutical giant said. The decision closes the chapter on a shot that was widely used in the ...
- AstraZeneca withdraws Covid-19 vaccine citing low demandon May 8, 2024 at 8:47 am
AstraZeneca is withdrawing its highly successful coronavirus vaccine, citing the availability of a plethora of new shots that has led to a decline in demand.
- AstraZeneca withdraws COVID-19 vaccine citing low demandon May 8, 2024 at 7:46 am
there is a surplus of available updated vaccines. This has led to a decline in demand for Vaxzevria, which is no longer being manufactured or supplied,” it said in a statement shared with CNN ...
- AstraZeneca to withdraw COVID vaccine globally as demand dipson May 8, 2024 at 7:10 am
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic.
- AstraZeneca to withdraw its COVID-19 vaccine globally as demand dips, rare side effects revealedon May 8, 2024 at 4:11 am
The pharmaceutical giant AstraZeneca said on Tuesday it is withdrawing its COVID-19 vaccine worldwide due to low demand and following reports that the vaccine caused rare side effects.
- AstraZeneca says it will withdraw COVID-19 vaccine globally as demand dipson May 7, 2024 at 7:18 pm
AstraZeneca said on Tuesday it had initiated the worldwide withdrawal of its COVID-19 vaccine due to a "surplus of available updated vaccines" since the pandemic.
via Bing News